Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States.
Read More…
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Phone973-605-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.16 million
Profitability
Miscellaneous
Employees346
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Immunomedics (NASDAQ:IMMU) Frequently Asked Questions
What is Immunomedics' stock symbol?
Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."
How were Immunomedics' earnings last quarter?
Immunomedics, Inc. (NASDAQ:IMMU) released its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.09. During the same period in the prior year, the business posted ($0.68) EPS. View Immunomedics' Earnings History.
When is Immunomedics' next earnings date?
What price target have analysts set for IMMU?
11 analysts have issued twelve-month target prices for Immunomedics' shares. Their predictions range from $18.00 to $40.00. On average, they expect Immunomedics' share price to reach $28.9091 in the next year. This suggests a possible upside of 107.6% from the stock's current price. View Analyst Price Targets for Immunomedics.
What is the consensus analysts' recommendation for Immunomedics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics.
What are Wall Street analysts saying about Immunomedics stock?
Here are some recent quotes from research analysts about Immunomedics stock:
- 1. HC Wainwright analysts commented, "We remind investors that sacituzumab previously achieved a 31% 6.8-month median progression-free survival (mPFS) which, in our view, compares favorably to chemotherapy’s effect in this patient population (10-13% ORR and 3-4 month mPFS). Accordingly, we reiterate our Buy rating, while reducing our 12-month price target from $28 to $26 to account for the removal of the second- line HR+, HER2- mBC setting from our assumptions. IMMU-132 filing resubmission remains on track for early 4Q19." (8/8/2019)
- 2. According to Zacks Investment Research, "Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. " (7/16/2019)
Has Immunomedics been receiving favorable news coverage?
Media headlines about IMMU stock have trended positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Immunomedics earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the next several days. View News Stories for Immunomedics.
Who are some of Immunomedics' key competitors?
Some companies that are related to Immunomedics include IPSEN S A/S (IPSEY), Neogen (NEOG), Quidel (QDEL), Myriad Genetics (MYGN), Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Heska (HSKA), Meridian Bioscience (VIVO), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC) and Trinity Biotech (TRIB).
What other stocks do shareholders of Immunomedics own?
Who are Immunomedics' key executives?
Immunomedics' management team includes the folowing people:
- Dr. Behzad Aghazadeh Ph.D., Exec. Chairman (Age 48)
- Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 59)
- Mr. Scott A. Canute MBA, Exec. Director (Age 58)
- Mr. Brendan Delaney, Chief Commercial Officer (Age 44)
- Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 52)
Who are Immunomedics' major shareholders?
Immunomedics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.89%), BlackRock Inc. (7.19%), Boxer Capital LLC (3.42%), Price T Rowe Associates Inc. MD (3.20%), Janus Henderson Group PLC (2.07%) and Janus Henderson Group PLC (2.07%). Company insiders that own Immunomedics stock include Avoro Capital Advisors Llc, Behzad Aghazadeh, Brian A Markison, Bryan Ball, Cynthia L Goldenberg, David M Goldenberg and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.
Which institutional investors are selling Immunomedics stock?
IMMU stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Price T Rowe Associates Inc. MD, Bank of America Corp DE, Foresite Capital Management III LLC, Candriam Luxembourg S.C.A., First Light Asset Management LLC, Morgan Stanley and TD Asset Management Inc.. View Insider Buying and Selling for Immunomedics.
Which institutional investors are buying Immunomedics stock?
IMMU stock was bought by a variety of institutional investors in the last quarter, including Boxer Capital LLC, BlackRock Inc., Nuveen Asset Management LLC, Marshall Wace LLP, Panagora Asset Management Inc., C WorldWide Group Holding A S, Rice Hall James & Associates LLC and Vanguard Group Inc.. Company insiders that have bought Immunomedics stock in the last two years include Avoro Capital Advisors Llc, Behzad Aghazadeh, Bryan Ball and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.
How do I buy shares of Immunomedics?
Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immunomedics' stock price today?
One share of IMMU stock can currently be purchased for approximately $13.9250.
How big of a company is Immunomedics?
Immunomedics has a market capitalization of $2.67 billion and generates $2.16 million in revenue each year. The biopharmaceutical company earns $-273,840,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Immunomedics employs 346 workers across the globe.View Additional Information About Immunomedics.
What is Immunomedics' official website?
How can I contact Immunomedics?
Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]
MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.
